Département de génétique médicale, Hôpital Timone enfants, Assistance-Publique Hôpitaux de Marseille, Marseille, France.
Aix Marseille Univ, INSERM, MMG, U1251, Marseille, France.
J Hum Genet. 2020 Mar;65(3):313-323. doi: 10.1038/s10038-019-0710-5. Epub 2019 Dec 18.
Charcot-Marie-Tooth disease (CMT) is a hereditary sensory-motor neuropathy characterized by a strong clinical and genetic heterogeneity. Over the past few years, with the occurrence of whole-exome sequencing (WES) or whole-genome sequencing (WGS), the molecular diagnosis rate has been improved by allowing the screening of more than 80 genes at one time. In CMT, except the recurrent PMP22 duplication accounting for about 60% of pathogenic variations, pathogenic copy number variations (CNVs) are rarely reported and only a few studies screening specifically CNVs have been performed. The aim of the present study was to screen for CNVs in the most prevalent genes associated with CMT in a cohort of 200 patients negative for the PMP22 duplication. CNVs were screened using the Exome Depth software on next generation sequencing (NGS) data obtained by targeted capture and sequencing of a panel of 81 CMT associated genes. Deleterious CNVs were identified in four patients (2%), in four genes: GDAP1, LRSAM1, GAN, and FGD4. All CNVs were confirmed by high-resolution oligonucleotide array Comparative Genomic Hybridization (aCGH) and/or quantitative PCR. By identifying four new CNVs in four different genes, we demonstrate that, although they are rare mutational events in CMT, CNVs might contribute significantly to mutational spectrum of Charcot-Marie-Tooth disease and should be searched in routine NGS diagnosis. This strategy increases the molecular diagnosis rate of patients with neuropathy.
腓骨肌萎缩症(CMT)是一种遗传性感觉运动神经病,其特征是临床和遗传异质性很强。在过去的几年中,随着外显子组测序(WES)或全基因组测序(WGS)的出现,可以同时筛选 80 多个基因,从而提高了分子诊断率。在 CMT 中,除了约占致病变异 60%的反复 PMP22 重复外,很少报道致病拷贝数变异(CNVs),并且仅进行了少数专门筛查 CNVs 的研究。本研究的目的是在排除 PMP22 重复的 200 名患者队列中筛选与 CMT 相关的最常见基因的 CNVs。使用靶向捕获和 81 个 CMT 相关基因的测序 panel 的下一代测序(NGS)数据,使用 Exome Depth 软件筛选 CNVs。在四个患者(2%)中发现了四个基因中的有害 CNVs:GDAP1、LRSAM1、GAN 和 FGD4。所有的 CNVs 均通过高分辨率寡核苷酸微阵列比较基因组杂交(aCGH)和/或定量 PCR 进行了确认。通过在四个不同基因中鉴定出四个新的 CNVs,我们证明,尽管它们在 CMT 中是罕见的突变事件,但 CNVs 可能对腓骨肌萎缩症的突变谱有重要贡献,并且应该在常规 NGS 诊断中进行搜索。该策略提高了神经病变患者的分子诊断率。